{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"30"}],"units":"Participants"}],"description":"Number of participants that are alive and disease free one year post transplant","groups":[{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"OG000","title":"P1_C1_5x10^6"},{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"OG001","title":"P1_C2_1x10^7"},{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"OG002","title":"P1_C3_5x10^7"},{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"OG003","title":"P1_C4_1X10^8"},{"description":"Patients receive elotuzumab IV over 2-5 hours on day -15 and -8, lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"OG004","title":"P2_1x10^8+Elotuzumab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 12 months","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Participants"}